Dr. Galia Blum is a senior lecturer in the Institute of Drug Research at the Faculty of Medicine of The Hebrew University of Jerusalem. She has authored scientific peer-reviewed papers and has five patents.
Dr. Blum’s lab develops novel small molecules that target various cancers and allow simultaneous tumor detection and therapeutic capabilities in models. A primary goal is to generate compounds, that when injected into the body, will reach cancerous tissue, bind to it and fluoresce, allowing for non-invasive disease detection. Shining visible light at the fluorescing tumors will cause these reagents to abolish the diseased tissue.
Dr. Blum received her B.S. in Chemistry from The Hebrew University; she conducted her doctoral studies in the laboratory of the acclaimed cancer researcher, Professor Alexander Levitzki, receiving the Polack Prize for Excellence in Studies and Research from the Silberman Institute of Life Sciences. Her postdoctoral work was conducted at the Stanford University School of Medicine. In 2013, Dr. Blum received a 1.5 million euro ERC Starting Grant for her research on Protease Activated X-Ray Contrast Agents for Molecular Imaging of Vulnerable Atherosclerotic Plaques and Cancer Development, using Spectral CT.